Targeted News Service

Johnson & Johnson announces ICOTYDE(r) (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
November 07, 2026

RARITAN, New Jersey, Nov. 7 [Category: BizPharmaceuticals] -- Johnson and Johnson Innovative Medicine posted the following news release:

* * *

Johnson & Johnson announces ICOTYDE(r) (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

*

New Brunswick, N.J. (November 7, 2026) - Johnson & Johnson (NYSE: JNJ) today announced positive resul . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form